The company’s CD38 x CD28 MAb is among recent clinical trial entrants.

The Hutchmed-originated savolitinib moves towards its first US approval.

The next-generation telisotuzumab adizutecan joins teliso-V in late-stage development.

Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials.

Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.

The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.

Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.

More efficient internalisation and release – not bystander activity – are the focus for this private ADC player.